NEUTRA CORP. Form 10-Q/A September 26, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

Amendment No. 1

(MARK ONE)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 31, 2017

or

[_] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to _____

Commission File Number: 0-55077

NEUTRA CORP.

(Exact name of registrant as specified in its charter)

<u>Nevada</u>	<u>27-4505461</u>
(State or other jurisdiction of Incorporation or	(IDC Freelows Heat'f'est's a New Lea)
organization)	(I.R.S. Employer Identification Number)
400 South 4th Street, Suite 500	
Las Vegas, Nevada	<u>89101</u>
(Address of principal executive offices)	(Zip code)
Registrant's telephone number, inc	cluding area code: <u>702-793-4121</u>
Indicate by check mark whether the registrant (1) has filed a Securities Exchange Act of 1934 during the preceding 12 morequired to file such reports), and (2) has been subject to such	onths (or for such shorter period that the registrant was
	Yes [X] No [_]
Indicate by check mark whether the registrant has submitted any, every Interactive Data File required to be submitted and (§232.405 of this chapter) during the preceding 12 months.	* *
Indicate by check mark whether the registrant is a large acce smaller reporting company, or an emerging growth company filer," "smaller reporting company" or "emerging growth company"	v. See the definitions of "large accelerated filer," "accelerated
Large accelerated filer [_] Non-accelerated filer [_] (Do not check is smaller reporting company)	Accelerated filer [_] Smaller reporting company [X] Emerging growth company [_]
If an emerging growth company, indicate by check mark if the period for complying with any new or revised financial acconstance. [_]	-
Indicate by check mark whether the registrant is a shell comp	pany (as defined in Rule 12b-2 of the Exchange Act).

Yes [_] No [X]

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date. As of September 18, 2017, 6,226,604 shares of common stock are issued and outstanding.

EXPLANATORY NOTE

The purpose of this Amendment No. 1 to the Registrant's Quarterly Report on Form 10-Q for the quarterly period ended July 31, 2017 ("Form 10-Q") is to submit Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T. Exhibit 101 consists of the Interactive Data Files from the Registrant's Form 10-Q for the quarterly period ended July 31, 2017, filed with the Securities and Exchange Commission on September 19, 2017.

Additionally, we corrected a typographical error in the CONSOLIDATED STATEMENTS OF CASH FLOWS on page 7. Under the "2017" column heading, the line item "Accrued interest payable" incorrectly stated a value of "22,493". The value has been corrected to "22,513".

No other changes were made to this report.

TABLE OF CONTENTS

PART I — FINANCIAL INFORMATION	4
Item 1. Financial Statements	4
Consolidated Balance Sheets	4
Consolidated Statements of Operations	5
Consolidated Statement of Stockholders' Deficit	6
Consolidated Statements of Cash Flows	7
Notes to the Unaudited Consolidated Financial Statements	8
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3. Quantitative and Qualitative Disclosures about Market Risk	15
Item 4. Controls and Procedures	15
PART II — OTHER INFORMATION	15

Item 1. Legal Proceedings	15
Item 1A. Risk Factors	15
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	15
Item 3. Defaults upon Senior Securities	16
Item 4. Mine Safety Disclosures	16
Item 5. Other Information	16
Item 6. Exhibits	16
- 2 -	
2	

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Certain statements in this report contain or may contain forward-looking statements. These statements, identified by words such as "plan", "anticipate", "believe", "estimate", "should", "expect" and similar expressions include our expectations objectives regarding our future financial position, operating results and business strategy. These statements are subject to known and unknown risks, uncertainties and other factors, which may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward - looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous assumptions and other factors that could cause our actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, our ability to secure suitable financing to continue with our existing business or change our business and conclude a merger, acquisition or combination with a business prospect, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk, U.S. and global competition, and other factors. Most of these factors are difficult to predict accurately and are generally beyond our control. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Readers should carefully review this report in its entirety, including but not limited to our financial statements and the notes thereto and the risks described in our Annual Report on Form 10-K for the fiscal year ended January 31, 2017. We advise you to carefully review the reports and documents we file from time to time with the Securities and Exchange Commission (the "SEC"), particularly our quarterly reports on Form 10-Q and our current reports on Form 8-K. Except for our ongoing obligations to disclose material information under the Federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.

OTHER PERTINENT INFORMATION

When used in this report, the terms, "we," the "Company," "our," and "us" refers to Neutra Corp., a Nevada corporation.

PART I — FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

NEUTRA CORP.

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

	,	July 31, 2017	January 31, 2017	
ASSETS				
CURRENT ASSETS				
Deposit	\$	10,293	\$	—
Total current assets		10,293		_
TOTAL ASSETS	\$	10,293	\$	_
LIABILITIES AND STOCKHOLDERS' EQUITY				
CURRENT LIABILITIES				
Accounts payable and accrued expenses	\$	420,335	\$ 471,477	7
Accounts payable to related party		122,584	83,692	
Cash overdraft		_	- 1,443	
Advances payable		3,450	3,450	0
Current portion of convertible notes payable, in default, net of				
discount of \$0 and \$112,323, respectively		84,857	54,385	
Current portion of accrued interest payable		20,141	13,698	
Total current liabilities		651,367	628,145	5
Convertible notes payable, net of discount of \$263,469 and				
\$278,882, respectively		44,228	28,815	
Accrued interest payable		33,854	18,596	
TOTAL LIABILITIES		729,449	675,556	6
COMMITMENTS AND CONTINGENCIES		_	_	
STOCKHOLDERS' DEFICIT Common stock, \$0.001 par value; 480,000,000 shares authorize 5,885,746 and 2,981,660 shares issued and outstanding at July 3				
2017 and January 31, 2017, respectively		5,886	2,982	
		1,000	1,000	0

Series E preferred stock, \$0.001 par value; 20,000,000 shares authorized; 1,000,000 shares issued or outstanding at July 31, 2017 and January 31, 2017, respectively

Additional paid-in capital	5,553,289	5,235,652
Accumulated deficit	(6,279,331)	(5,915,190)
Total stockholders' deficit	(719,156)	(675,556)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT \$ 10,293 \$ -

NEUTRA CORP. CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Six months ended July 31,			Three months ended July 31,		
	2017	,	2016	2017		2016
REVENUE	\$ _	\$	—\$	_	\$	_
OPERATING EXPENSES General and administrative expenses	90,443		208,457	34,539		94,106
LOSS FROM OPERATIONS	(90,443)		(208,457)	(34,539)		(94,106)
OTHER INCOME (EXPENSE) Interest expense Gain on note modification Total other income (expense)	(273,698) — (273,698)		(152,197) 12,400 (139,797)	(119,590) — (119,590)		(75,582) 4,772 (70,810)
NET LOSS	\$ (364,141)	\$	(348,254) \$	(154,129)	\$	(164,916)
NET LOSS PER COMMON SHARE – Basic and fully diluted	\$ (0.09)	\$	(0.19) \$	(0.03)	\$	(0.08)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Basic and fully diluted	4,222,302		1,858,898	4,843,317		1,952,626

NEUTRA CORP.

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT

(UNAUDITED)

	Commo			Preferr		tock	Additional Paid-In	Accumulated	
	Shares	Aı	mount	Shares	A	mount	Capital	Deficit	Total
BALANCE, January 31, 2017	2,981,660	\$	2,982	1,000,000	\$	1,000 \$	5,235,652	\$ (5,915,190)\$	(675,556)
Common stock issued for debt conversion Beneficial conversion discount on issuance of	2,904,086		2,904	_	_	_	208,711	_	211,615
convertible note payable Net loss	_ _	-	<u>-</u>		-	_	108,926		108,926 (364,141)
BALANCE, July 31, 2017	5,885,746	\$	5,886	1,000,000	\$	1,000 \$	5,553,289	\$ (6,279,331) \$	(719,156)

NEUTRA CORP.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Six months en 2017	nded July	y 31, 2016	
\$	(364,141)	\$	(348,254)	
	251,185 —		125,617 (12,400)	
	(10,293) (52,605) 38,892 22,513 (114,449)		18,017 — 26,581 (190,439)	
	— 114,449 114,449		67,986 123,350 191,336	
	_		897	
	_		284	
\$	_	\$	1,181	
		*		
\$ \$		\$ \$	_	
\$ \$ \$	— 108,926 211.615	\$ \$ \$	67,986 207,986 80,128	
	\$ \$ \$ \$ \$	\$ (364,141) 251,185 (10,293) (52,605) 38,892 22,513 (114,449) 114,449 114,449 \$	\$ (364,141) \$ 251,185 (10,293) (52,605) 38,892 22,513 (114,449) 114,449 114,449 \$ \$ \$ \$ \$ \$ \$ \$ \$ 108,926	

NEUTRA CORP.

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

JULY 31, 2017

Note 1. General Organization and Business

Neutra Corp. was incorporated in Nevada on January 11, 2011 to market and participate in the nutraceutical space by bringing products derived from all natural and organic origins. Along with participating in the actual nutraceutical products, we plan to research and bring new technology to the nutraceutical space. Nutraceutical natural medicine is an alternative system that focuses on natural remedies and the body's vital ability to heal and maintain itself. One of the nutraceutical sub-markets is the new thriving medical cannabis market, in which we intend to participate. We intend to entrust the manufacturing to a nutraceutical contractor to private label all of our products and to sell them under our unique brand. We have established a fiscal year end of January 31.

As the global cannabis market grows exponentially, it is constantly in need of better technologies and products to be more efficient in how it grows, what it grows and how it consumes cannabis and its related products. From lighting to dosage devices, from pesticide replacements to plant enhancers, Neutra Corp. is constantly combing the industry for the latest and greatest to test, prove and bring to market.

We have not generated any revenues to date and our activities have been limited to developing our business plan and research and development of products. We will not have the necessary capital to fully develop or execute our business plan until we are able to secure additional financing. There can be no assurance that such financing will be available on suitable terms. We need to raise additional funds in order to implement our business plan. Our current cash on hand is insufficient to commercialize our products or fully develop our business strategy. If we are unable to raise adequate additional funds or if those funds are not available on terms that are acceptable to us, we will not be able to execute our business plan and we may cease operations.

Note 2. Going Concern

The accompanying financial statements have been prepared assuming that we will continue as a going concern. For the six months ended July 31, 2017, we had a net loss of \$364,141 and negative cash flow from operating activities of \$114,449. As of July 31, 2017, we had negative working capital of \$641,074. Management does not anticipate having positive cash flow from operations in the near future.

These factors raise a substantial doubt about our ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

We do not have the resources at this time to repay its credit and debt obligations, make any payments in the form of dividends to its shareholders or fully implement its business plan. Without additional capital, the we will not be able to remain in business.

Management has plans to address the Company's financial situation as follows:

In the near term, management plans to continue to focus on raising the funds necessary to implement our business plan. Management will continue to seek out debt financing to obtain the capital required to meet our financial obligations. There is no assurance, however, that lenders will continue to advance capital to us or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raise doubts about our ability to continue as a going concern.

In the long term, management believes that our projects and initiatives will be successful and will provide cash flow, which will be used to finance our future growth. However, there can be no assurances that our planned activities will be successful, or that we will ultimately attain profitability. Our long-term viability depends on its ability to obtain adequate sources of debt or equity funding to meet current commitments and fund the continuation of its business operations, and our ability to achieve adequate profitability and cash flows from operations to sustain its operations.

Note 3. Summary of Significant Accounting Policies

Interim Financial Statements

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and such adjustments are of a normal recurring nature. These consolidated financial statements should be read in conjunction with the consolidated financial statements for the fiscal year ended January 31, 2017 and notes thereto and other pertinent information contained in our Form 10-K that we filed with the Securities and Exchange Commission (the "SEC").

The results of operations for the six-month period ended July 31, 2017 are not necessarily indicative of the results to be expected for the full fiscal year ending January 31, 2018.

Consolidated Financial Statements

The consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiaries from the date of their formations. Significant intercompany transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Deposits

Deposits represent cash on deposit with the Company's attorney.

Earnings (Loss) per Common Share

We compute basic and diluted earnings per common share amounts in accordance with ASC Topic 260, *Earnings per Share*. The basic earnings (loss) per common share are calculated by dividing our net income available to common shareholders by the weighted average number of common shares outstanding during the year. The diluted earnings (loss) per common share are calculated by dividing our net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. There are no dilutive shares outstanding for any periods reported.

Recently Issued Accounting Pronouncements

We have reviewed the FASB issued Accounting Standards Update ("ASU") accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporation's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration.

Note 4. Related Party Transactions

During the six months ended July 31, 2017, we incurred salary expense of \$22,500 related to services provided by our CEO Christopher Brown. We paid Mr. Brown \$37,500 in salary during the six months ended July 31, 2017. As of July 31, 2017, we owe Mr. Brown \$89,200, which is recorded on the balance sheet in "Accounts Payable – Related Party."

Note 5. Advances

As of July 31, 2017 and January 31, 2017, we had amounts due under advances of \$3,450 at each period. These advances are not collateralized, non-interest bearing and are due on demand.

Note 6. Convertible Notes Payable

Convertible notes payable consists of the following as of July 31, 2017 and January 31, 2017:

	July 31, 2017	January 31, 2017
Convertible note, dated July 31, 2015, bearing interest at 10% per		
annum, maturing on July 31, 2017 and convertible into shares of		
common stock at \$0.01 per share, in default	72,640	73,940
Convertible note, dated October 31, 2015, bearing interest at 10%		
per annum, maturing on October 31, 2018 and convertible into		
shares of common stock at \$0.50 per share	156,976	156,976
Convertible note, dated January 31, 2016, bearing interest at 10%		
per annum, maturing on January 31, 2019 and convertible into		
shares of common stock at a 60% discount to the market price	82,735	82,735
Convertible note, dated March 14, 2016, bearing interest at 8%		
per annum, maturing on March 14, 2017, and convertible into		
shares of common stock at a4 5% discount to the market price, in		
default	1,217	1,217
Convertible note, dated March 14, 2016, bearing interest at 8%		
per annum, maturing on March 14, 2017, and convertible into		
shares of common stock at a 45% discount to the market price	_	16,551
Convertible note, dated May 26, 2016, bearing interest at 8% per		
annum, maturing on May 26, 2017, and convertible into shares of		
common stock at a 45% discount to the market price, in default	67,986	67,986
Convertible note, dated May 26, 2016, bearing interest at 8% per		
annum, maturing on May 26, 2017, and convertible into shares of		
common stock at a 45% discount to the market price	_	75,000
Convertible note, dated May 26, 2016, bearing interest at 8% per		
annum, maturing on May 26, 2017, and convertible into shares of		
common stock at a 45% discount to the market price, in default	11,000	
Total convertible notes payable	\$,	\$ 474,405
Less: current portion of convertible notes payable	(84,857)	(166,708)
Less: discount on noncurrent convertible notes payable	(263,469)	(278,882)
Convertible notes payable, net of discount	\$ 44,228	\$ 28,815
Current portion of convertible notes payable	\$ 84,857	\$ 166,708
Less: discount on current convertible notes payable	_	(112,323)
Convertible notes payable, net of discount	\$ 84,857	\$ 54,385

Issuance of Convertible Promissory Notes

During the six months ended July 31, 2017 and 2016, we issued Convertible Promissory Notes. The Convertible Promissory Notes bear interest and are payable at maturity along with accrued interest. The Convertible Promissory Notes and unpaid accrued interest are convertible into common stock at the option of the holder.

Date Issued March 14, 2016 April 30, 2016	Maturity Date March 14, 2017 April 30, 2019	Interest Rate 8% 10%	Conversion Rate 45% discount 60% discount	\$ Amount of Note 65,000 67,986
Date Issued/Funded February 9, 2017 April 27, 2017	Maturity Date March 14, 2017 May 27, 2017	Interest Rate 8% 8%	Conversion Rate 45% discount 45% discount	\$ Amount of Note 48,449 75,000
		- 10 -		

We evaluated the terms of the new notes in accordance with ASC Topic No. 815 - 40, *Derivatives and Hedging - Contracts in Entity's Own Stock* and determined that the underlying common stock is indexed to the Company's common stock. We determined that the conversion features did not meet the definition of a liability and therefore did not bifurcate the conversion feature and account for it as a separate derivative liability. We then evaluated the conversion feature for a beneficial conversion feature. The effective conversion price was compared to the market price on the date of the note and was deemed to be less than the market value of underlying common stock at the inception of the note. Therefore, each of the above notes was fully discounted with a beneficial conversion discount o the date of issuance. We recorded the beneficial conversion discounts as an increase in additional paid-in capital and a discount to the Convertible Notes Payable. Discounts to the Convertible Notes Payable are amortized to interest expense over the life of the respective notes using the effective interest method. During the years ended January 31, 2017 and 2016, we recorded amortization of discounts on convertible notes payable and recognized interest expense of \$143,413 and \$64,354, respectively.

Modifications of Convertible Promissory Notes

On March 14, 2016, a third party purchased the outstanding principal and accrued interest of our convertible promissory noted dated April 30, 2015. We came to an agreement with the purchaser to change the conditions of the note. Principal and accrued interest on the existing note were refinanced into \$68,991 of principal on the new note. The maturity date was changed to March 14, 2017. The interest rate was lowered to 8%, and the conversion rate was change to a 45% discount to the lowest trading price over the preceding 20 days with a floor on the conversion price of \$0.00005.

We evaluated the terms of the new note in accordance with ASC Topic No. 815 - 40, *Derivatives and Hedging - Contracts in Entity's Own Stock* and determined that the underlying common stock is indexed to the Company's common stock. We determined that the conversion feature did not meet the definition of a liability, because there was a floor on the conversion price and the Board of Directors has the intent and ability to increase the number of outstanding shares if necessary to meet the conversion requirements of the note. We did not bifurcate the conversion feature and account for it as a separate derivative liability. We then evaluated the conversion feature for a beneficial conversion discount. The effective conversion price was compared to the market price on the date of the note and was deemed to be less than the market value of underlying common stock at the inception of the note. Therefore, we transferred the existing discount of \$68,991 on the note to the new modified note on March 14, 2016. We recorded the beneficial conversion discount as an increase in additional paid-in capital and a discount to the Convertible Notes Payable.

We evaluated the terms of the modified note in accordance with ASC Topic No. 470 – 50, *Modifications and Extinguishments*. We determined this change in terms did constitute a modification. Therefore, we recognized a \$7,628 gain on debt modification on March 14, 2016.

Convertible Promissory Notes Issued for Cash

On March 14, 2016, we issued a convertible promissory note to a third party for cash. The note (the "front-end note") was in the amount of \$65,000, and it matures on March 14, 2017. The note bears interest at 8% per year and is convertible into shares of our common stock at a 45% discount to our lowest trading price over the preceding 20 days with a floor on the conversion price of \$0.00005.

We evaluated the terms of the note in accordance with ASC Topic No. 815 - 40, *Derivatives and Hedging - Contracts in Entity's Own Stock* and determined that the underlying common stock is indexed to the Company's common stock. We determined that the conversion features did not meet the definition of a liability and therefore did not bifurcate the conversion feature and account for it as a separate derivative liability. We then evaluated the conversion feature for a beneficial conversion feature. The effective conversion price was compared to the market price on the date of the note and was deemed to be less than the market value of underlying common stock at the inception of the note. Therefore, we recognized beneficial conversion discount of \$68,991 on March 14, 2016. We recorded the beneficial conversion discount as an increase in additional paid-in capital and a discount to the Convertible Notes Payable. Discounts to the Convertible Notes Payable are amortized to interest expense using the effective interest method over the life of the respective notes.

On the same date we issued a second note (the "back-end note") in the amount of \$65,000 in exchange for a note receivable in the same amount. The back-end note matures on March 14, 2017. The note bears interest at 8% per year and is convertible into shares of our common stock at a 45% discount to our lowest trading price over the preceding 20 days with a floor on the conversion price of \$0.00005. The Company received proceeds of \$16,551 on January 6, 2017 and the remaining proceeds of \$48,449 on February 9, 2017. The note was secured by the note receivable for \$65,000 from the same party.

On May 26, 2016, we issued a convertible promissory note to a third party for cash. The note (the "front-end note") was in the amount of \$75,000, and it matures on May 26, 2017. The note bears interest at 8% per year and is convertible into shares of our common stock at a 45% discount to our lowest trading price over the preceding 20 days with a floor on the conversion price of \$0.00005.

On the same date we issued a second note (the "back-end note") in the amount of \$75,000 in exchange for a note receivable in the same amount. The back-end note matures on May 26, 2017. The note bears interest at 8% per year and is convertible into shares of our common stock at a 45% discount to our lowest trading price over the preceding 20 days with a floor on the conversion price of \$0.00005. The Company received the proceeds of this note on April 27, 2017. The note was secured by the note receivable for \$75,000 from the same party.

Conversions to Common Stock

During six months ended July 31, 2016, the holders of our convertible promissory notes converted \$80,128 of principal and accrued interest into 343,719 shares of our common stock. Of the shares converted, 94,000 shares, valued at \$94, had not been issued as of July 31, 2016, and as such have been classified as stock payable. No gain or loss was recognized on the conversions as they occurred within the terms of the agreement which provided for conversion.

During six months ended July 31, 2017, the holders of our convertible promissory notes converted \$211,615 of principal and accrued interest into 2,904,086 shares of our common stock. See Note 10. No gain or loss was recognized on the conversions as they occurred within the terms of the agreement which provided for conversion.

Note 7. Stockholders' Equity

Conversions to common stock

During six months ended July 31, 2017, the holders of our convertible notes elected to convert principal and interest into shares of common stock as detailed below:

	Amount	Number of		
Date	Converted	Shares Issued		
February 13, 2017	\$ 16,619	151,085		
February 22, 2017	25,066	227,870		
March 6, 2017	23,629	214,807		
March 21, 2017	12,784	102,168		
March 30, 2017	21,346	170,595		
April 7, 2017	10,690	92,558		
April 20, 2017	35,372	321,567		
May 22, 2017	10,055	130,582		

Edgar Filing: NEUTRA CORP. - Form 10-Q/A

May 30, 2017	650	65,000
June 2, 2017	10,079	160,748
June 2, 2017	650	65,000
June 13, 2017	11,113	202,060
June 30, 2017	10,140	290,344
July 12, 2017	10,167	308,078
July 25, 2017	13,255	401,624
Total	\$ 211,615	2,904,086

During six months ended July 31, 2016, the holders of our convertible notes elected to convert principal and interest into shares of common stock as detailed below:

	1	Amount	Number of
Date	C	onverted	Shares Issued
March 17, 2016	\$	5,001	8,266
March 30, 2016		10,031	16,887
April 6, 2016		850	85,000
April 12, 2016		11,065	20,322
April 21, 2016		20,158	40,271
May 18, 2016		22,074	49,857
May 31, 2016		10,009	29,116
June 28, 2016		940	94,000
Total	\$	80,128	343,719

Note 8. Subsequent Events

On August 9, 2017, we issued 340,858 shares of common stock as a result of the conversion of principal of \$11,000 on a convertible note payable.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

Neutra Corp. was incorporated in Nevada on January 11, 2011 to market and participate in the nutraceutical space by bringing products derived from all natural and organic origins. Along with participating in the actual nutraceutical products, we plan to research and bring new technology to the nutraceutical space. Nutraceutical natural medicine is an alternative system that focuses on natural remedies and the body's vital ability to heal and maintain itself. One of the nutraceutical sub-markets is the new thriving medical cannabis market, in which we intend to participate. We intend to entrust the manufacturing to a nutraceutical contractor to private label all of our products and to sell them under our unique brand. We have established a fiscal year end of January 31.

As the global cannabis market grows exponentially, it is constantly in need of better technologies and products to be more efficient in how it grows, what it grows and how it consumes cannabis and its related products. From lighting to dosage devices, from pesticide replacements to plant enhancers, Neutra Corp. is constantly combing the industry for the latest and greatest to test, prove and bring to market.

We have not generated any revenues to date and our activities have been limited to developing our business plan and research and development of products. We will not have the necessary capital to fully develop or execute our business plan until we are able to secure additional financing. There can be no assurance that such financing will be available on suitable terms. We need to raise additional funds in order to implement our business plan. Our current cash on hand is insufficient to commercialize our products or fully develop our business strategy. If we are unable to raise adequate additional funds or if those funds are not available on terms that are acceptable to us, we will not be able to execute our business plan and we may cease operations.

Critical Accounting Policies

We prepare our Consolidated financial statements in conformity with GAAP, which requires management to make certain estimates and apply judgments. We base our estimates and judgments on historical experience, current trends, and other factors that management believes to be important at the time the condensed Consolidated financial statements are prepared. On a regular basis, we review our accounting policies and how they are applied and disclosed in our condensed consolidated financial statements.

While we believe that the historical experience, current trends and other factors considered support the preparation of our condensed consolidated financial statements in conformity with GAAP, actual results could differ from our estimates and such differences could be material.

For a full description of our critical accounting policies, please refer to Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report for the year ended January 31, 2017 on Form 10-K.

Results of Operations

Six months ended July 31, 2017 compared to the six months ended July 31, 2016.

General and Administrative Expenses

We recognized general and administrative expenses of \$90,443 and \$208,457 for the six months ended July 31, 2017 and 2016, respectively. The decrease is primarily due to reduced professional fees and reduced contributions to joint ventures.

Interest Expense

Interest expense increased from \$152,197 for the six months ended July 31, 2016 to \$273,698 for the six months ended July 31, 2017. During the six months ended July 31, 2017, we amortized \$251,185 of the discount on our convertible notes, compared to \$125,617 for the comparable period of 2016. This was driven by fewer conversions of our convertible notes payable into common stock. The remaining change is due to interest expense on our convertible promissory notes.

Gain on note modification

We recognized a gain on note modification of \$0 and \$12,400 for the six months ended July 31, 2017 and 2016, respectively. The gain is due the convertible promissory note issued on March 14, 2016.

Net Loss

We incurred a net loss of \$364,141 for six months ended July 31, 2017 as compared to \$348,254 for the comparable period of 2016. The increased net loss is due to the derivative liability on our new convertible promissory notes, offset by reductions in professional fees and interest expense.

Three months ended July 31, 2017 compared to the three months ended July 31, 2016.

General and Administrative Expenses

We recognized general and administrative expenses of \$34,539 and \$94,106 for the three months ended July 31, 2017 and 2016, respectively. The decrease is primarily due to reduced professional fees and reduced contributions to joint ventures.

Interest Expense

Interest expense increased from \$75,582 for the three months ended July 31, 2016 to \$119,590 for the three months ended July 31, 2017. During the three months ended July 31, 2017, we amortized \$109,772 of the discount on our convertible notes, compared to \$61,263 for the comparable period of 2016. This was driven by fewer conversions of our convertible notes payable into common stock. The remaining change is due to interest expense on our convertible promissory notes.

Gain on note modification

We recognized a gain on note modification of \$0 and \$4,772 for the three months ended July 31, 2017 and 2016, respectively. The gain is due the convertible promissory note issued on March 14, 2016.

Net Loss

We incurred a net loss of \$154,129 for three months ended July 31, 2017 as compared to \$164,916 for the comparable period of 2016. The increased net loss is due to the derivative liability on our new convertible promissory notes, offset by reductions in professional fees and interest expense.

Liquidity and Capital Resources

At July 31, 2017, we had cash on hand of \$0. We have negative working capital of \$641,074. Net cash used in operating activities for the six months ended July 31, 2017 was \$114,449. Cash on hand is adequate to fund our operations for less than one month. We do not expect to achieve positive cash flow from operating activities in the near future. We will require additional cash in order to implement our business plan. There is no guarantee that we will be able to attain fund when we need them or that funds will be available on terms that are acceptable to us. We have no material commitments for capital expenditures as of July 31, 2017.

Additional Financing

Additional financing is required to continue operations. Although actively searching for available capital, we do not have any current arrangements for additional outside sources of financing and cannot provide any assurance that such financing will be available.

Off Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

This item is not applicable to smaller reporting companies.

ITEM 4. CONTROLS AND PROCEDURES

Management's Report on Internal Control over Financial Reporting

We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of July 31, 2017. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of July 31, 2017, our disclosure controls and procedures were not effective to ensure that information required to be disclosed in reports filed by us under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

- 1. As of July 31, 2017, we did not maintain effective controls over the control environment. Specifically, we have not developed and effectively communicated to our employees our accounting policies and procedures. This has resulted in inconsistent practices. Further, the Board of Directors does not currently have any independent members and no director qualifies as an audit committee financial expert as defined in Item 407(d)(5)(ii) of Regulation S-K. Since these entity level programs have a pervasive effect across the organization, management has determined that these circumstances constitute a material weakness.
- 2. As of July 31, 2017, we did not maintain effective controls over financial statement disclosure. Specifically, controls were not designed and in place to ensure that all disclosures required were originally addressed in our financial statements. Accordingly, management has determined that this control deficiency constitutes a material weakness.

Our management, including our principal executive officer and principal financial officer, who is the same person, does not expect that our disclosure controls and procedures or our internal controls will prevent all error or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

Change in Internal Controls Over Financial Reporting

There was no change in our internal controls over financial reporting that occurred during the period covered by this report, which has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We know of no material, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered beneficial shareholder are an adverse party or has a material interest adverse to us.

ITEM 1A. RISK FACTORS

This item is not applicable to smaller reporting companies.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

There were no sales of unregistered equity securities during the six months ended July 31, 2017.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

We have not defaulted upon senior securities.

ITEM	4. MINE SAFETY DISCLOSURES
This it	em is not applicable to the Company.
ITEM	5. OTHER INFORMATION
None.	
ITEM	6. EXHIBITS
3.1	Articles of Incorporation (1)
3.2	Bylaws (1)
14.1	Code of Ethics (1)
21	Subsidiaries of the Registrant (2)
31.1	Rule 13(a)-14(a)/15(d)-14(a) Certification of principal executive officer and principal financial and accounting officer. (2)
32.1	Section 1350 Certification of principal executive officer and principal financial accounting officer. (2)
101	XBRL data files of Financial Statement and Notes contained in this Quarterly Report on Form 10-Q. (2) (3
	corporated by reference to our Form S-1 filed with the Securities and Exchange Commission on February 24
(2) Fil	ed or furnished herewith.

(3) In accordance with Regulation S-T, the Interactive Data Files in Exhibit 101 to the Quarterly Report on Form 10-Q shall be deemed "furnished" and not "filed."

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Neutra Corp.

Date: September 26, 2017 BY: /s/ Christopher Brown

Christopher Brown

President, Secretary, Treasurer, Principal Executive

Officer,

Principal Financial and Accounting Officer, and Sole

Director

- 16 -